Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Quality, compliance and lifecycle regulatory services / Post-market surveillance, vigilance and product-safety lifecycle services

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Post-market surveillance, vigilance and product-safety lifecycle services

Ongoing post-market obligations for regulated products: PMS plans and reports (PMSR/PSUR), PMCF and post-approval commitments, vigilance case processing and signal detection, trend reporting, recall and field-action management, and safety data management for devices, IVDs and medicines. Buyer is the manufacturer; the job is to keep the product's safety file current and defensible with regulators; the trigger is a regulatory reporting cycle, a safety signal, a complaint surge or a new post-market obligation.

Market size
$7.4B
$7.4B ($5.6B–$9.2B) · 2025 · Bottom-up
Growth
+10.0%
$11.9B by 2030
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
1 source · Bottom-up
Level
Niche
Segmented by
Customer type
Buyers
Pharma, biotech, medical-device and IVD manufacturers with marketed products (domestic and export)
Buying centre
Head of Pharmacovigilance / PV System Owner (owner), Medical Safety or Device Safety lead, Regulatory Affairs, and the Safety Governance Committee / Qualified Person
Buying triggers
  • EU MDR post-market surveillance module and PMCF obligations
  • Annual PMSR/PSUR and trend-reporting cycles
  • New safety signals, complaints or field actions requiring regulatory notification
  • Post-approval commitments and label or IFU changes
Pains
  • Safety data scattered across complaint, clinical and quality systems
  • Manual case processing and reporting that misses timelines
  • Inability to demonstrate signal detection and risk-benefit to regulators
  • Rising complaint volumes from installed base without scalable process
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability—
Growth—

How this was sized

$7.4B ($5.6B–$9.2B) · 2025 · Bottom-up

Published anchor: PV services and software of USD 8.6–11.8B in 2025, forecast USD 13.5–24.8B by 2030–2034 at 5.6–15.9% p.a. [1]. This niche is services only, so software (safety databases, case-management platforms) is excluded: assume software is 25–35% of the published pool, leaving services of USD 5.6–9.2B (midpoint USD 7,400M). Arithmetic: 8,600 x 0.75 = 6,450; 11,800 x 0.65 = 7,670; range 5,600–9,200 with midpoint 7,400. Forecast: 7,400 x 1.10^5 = USD 11,918M, rounded to USD 11,900M in 2030, using a mid-point of the published 5.6–15.9% CAGR range. The published figure is pharma-focused and excludes device PMS/vigilance, which would add; the software-exclusion share is an assumption. Low confidence.

Alongside it in Quality, compliance and lifecycle regulatory services

// Sell into Post-market surveillance, vigilance and product-safety lifecycle services

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.